Page 27 - JCTR-9-6

Miyake et al. | Journal of Clinical and Translational Research 2023; 9(6): 381-391 391
Harvey HA, et al. Neoadjuvant chemotherapy for muscle- cell carcinoma. J Comput Assist Tomogr 2018;42:204-10.
invasive bladder cancer: A systematic review and two-step [22] Honda Y, Nakamura Y, Teishima J, Goto K, Higaki T,
meta-analysis. Oncologist 2016;21:708-15. Narita K, et al. Clinical staging of upper urinary tract
[11] Iyer G, Tully CM, Zabor EC, Bochner BH, Dalbagni G, urothelial carcinoma for T staging: Review and pictorial
Herr HW, et al. Neoadjuvant gemcitabine-cisplatin plus essay. Int J Urol 2019;26:1024-32.
radical cystectomy-pelvic lymph node dissection for [23] Gschwend JE, Heck MM, Lehmann J, Rübben H,
muscle-invasive bladder cancer: A 12-year experience. Albers P, Wolff JM, et al. Extended versus limited lymph
Clin Genitourin Cancer 2020;18:387-94. node dissection in bladder cancer patients undergoing
[12] Kuwada M, Miyake M, Gotoh D, Tatsumi Y, Nakai Y, radical cystectomy: Survival results from a prospective,
Anai S, et al. Pretreatment platelet-to-lymphocyte ratio as randomized trial. Eur Urol 2019;75:604-11.
biomarker for neoadjuvant chemotherapy prior to radical [24] Miyake M, Tatsumi Y, Fujimoto K, Nagao K, Sakano S,
cystectomy in muscle-invasive bladder cancer. J Nara Med Matsuyama H, et al. Changes in oncological outcomes
Assoc 2017;68:29-41. after radical nephroureterectomy in patients with upper
[13] Miura Y, Hatakeyama S, Tanaka T, Fujita N, Horiguchi H, urinary tract urothelial carcinoma treated in the last two
Okuyama Y, et al. Prognostic impact of eligibility for decades: a retrospective analysis based on a multicenter
adjuvant immunotherapy in locally advanced urothelial collaborative study. Jpn J Clin Oncol 2016;46:1148-55.
cancer. BJUI Compass 2022;3:146-53. [25] Kondo T, Hashimoto Y, Kobayashi H, Iizuka J, Nakazawa H,
[14] Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Ito F, et al. Template-based lymphadenectomy in urothelial
Valderrama BP, Tomita Y, et al. Adjuvant nivolumab versus carcinoma of the upper urinary tract: Impact on patient
placebo in muscle-invasive urothelial carcinoma. N Engl J survival. Int J Urol 2010;17:848-54.
Med 2021;384:2102-14. [26] Grivas P, Agarwal N, Pal S, Kalebasty AR, Sridhar SS,
[15] Yan C, Huang M, Swetlik C, Toljan K, Mahadeen AZ, Bena J, Smith J, et al. Avelumab first-line maintenance in locally
et al. Predictors for the development of neurological immune- advanced or metastatic urothelial carcinoma: Applying
related adverse events of immune checkpoint inhibitors and clinical trial findings to clinical practice. Cancer Treat Rev
impact on mortality. Eur J Neurol 2023;30:3221-7. 2021;97:102187.
[16] Caiati C, Jirillo E. Immune checkpoint inhibitor-mediated [27] Miyake M, Shimizu T, Nishimura N, Kiba K, Maesaka F,
cardiovascular disease: the dark side of the monoclonal Oda Y, et al. response to pembrolizumab after dose-reduced
anti-body therapy against cancer. Endocr Metab Immune cisplatin plus gemcitabine chemotherapy is inferior to
Disord Drug Targets 2023;23:1365-7. that after carboplatin plus gemcitabine chemotherapy
[17] Defoe M, Bermas BL. Rheumatologic immune checkpoint in cisplatin-unfit patients with advanced Urothelial
inhibitor-related adverse events. Curr Opin Rheumatol Carcinoma. Clin Genitourin Cancer 2022;20:196.e1-9.
2023;35:141-8. [28] Kato M, Kobayashi T, Matsui Y, Ito K, Hikami K, Yamada T,
[18] Iwamoto Y, Kimura T, Iwamoto H, Sanada J, Fushimi Y, et al. Impact of the objective response to and number of cycles
Katakura Y, et al. Incidence of endocrine-related of platinum-based first-line chemotherapy for metastatic
immune-related adverse events in Japanese subjects with urothelial carcinoma on overall survival of patients treated
various types of cancer. Front Endocrinol (Lausanne) with pembrolizumab. Int J Urol 2021;28:1261-7.
2023;14:1079074. [29] Ferro M, Chiujdea S, Vartolomei MD, Bove P, Porreca A,
[19] Galsky MD, Witjes AA, Gschwend JE, Schenker M, Busetto GM, et al. Advanced Age Impacts Survival after Radical
Valderrama BP, Bamias A, et al. Extended follow- Nephroureterectomy for Upper Tract Urothelial Carcinoma.
up results from the CheckMate 274 trial. J Clin Oncol Clin Genitourin Cancer 2023:S1558-7673(23)00184-2.
2023;41 Suppl 6:LBA443. [30] Ferro M, Crocetto F, Tataru S, Barone B, Dolce P,
[20] Vellinga A, Cormican M, Hanahoe B, Bennett K, Lucarelli G, et al. Predictors of efficacy of immune
Murphy AW. Opt-out as an acceptable method of obtaining checkpoint inhibitors in patients with advanced urothelial
consent in medical research: A short report. BMC Med Res carcinoma: A systematic review and meta-analysis. Clin
Methodol 2011;11:40. Genitourin Cancer 2023;21:574-83.
[21] Mammen S, Krishna S, Quon M, Shabana WM, Hakim SW, [31] Mori K, Katayama S, Laukhtina E, Schuettfort VM,
Flood TA, et al. Diagnostic accuracy of qualitative and Pradere B, Quhal F, et al. Discordance between clinical and
quantitative computed tomography analysis for diagnosis pathological staging and grading in upper tract urothelial
of pathological grade and stage in upper tract urothelial carcinoma. Clin Genitourin Cancer 2022;20:95.e1-95.e6.

Publisher’s note
AccScience Publishing remains neutral with regard to jurisdictional
claims in published maps and institutional affiliations.

DOI: http://dx.doi.org/10.18053/jctres.09.202306.23-00106